Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist . Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain important for appetite regulation. Tirzepatide has been shown to decrease food intake among these other benefits:
Keeping our bodies in shape, active, and mobile is a huge part of our quality of life. This may be more important for some than others. Some of us have physically demanding jobs, and others participate in sports or other activities that require optimal physical performance. For some, being active is daily or up to 3-4 times a week. For others, the only time to get out and be active is on the weekend. No matter what situation you find yourself in, you want to be able to perform. Our bodies are indeed capable of doing great things, but in the process of maintaining our active lifestyle, there is always the risk of injury.
An experimental drug from Eli Lilly has the potential to provide greater weight loss benefits than any drug currently on the market. The experimental drug, retatrutide, helped people lose, on average, about 24% of their body weight, the equivalent of about 58 pounds, in a mid-stage clinical trial. This was announced at the American Diabetes Association's annual meeting in San Diego. The findings were also published in The New England Journal of Medicine.
Recover faster with peptide therapy! Here are three game-changing peptides shown to help aid in recovery post-injury or surgery.
